2021 MO – Experimental Tubulointerstitial Disease

D ROJAS-CANALES 1,3, E TUCKER 3, K MCNICHOLAS 3, A MEHDORN 2, J GLEADLE 1,3 1Department of Renal Medicine, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, 2Flinders Centre for Innovation in Cancer, Department of Gastroenterology and...
  • 27 May 2021
Read More
HARLEY G1, KATERELOS M1, GLEICH K1, MOUNT P1,2, POWER D1,2 1Austin Health, Melbourne, Australia, 2University of Melbourne, Melbourne, Australia Aim: To determine if modification of glycolysis has a critical role in metformin’s protective effects against renal fibrosis. Background: Metformin has...
  • 26 May 2021
Read More
M Khan1,2,3,4,P  Nag3,5, K Giuliani2,3,5,X  Wang3,5, A Grivei3,5, W Hoy1,7, H Healy1,2,3,5, V Dewan1,7, G Gobe1,2,6, A Kassianos2,3,5  1NHMRC CKD CRE (CKD.QLD), University of Queensland , Brisbane,, Australia, 2Faculty of Medicine, University of Queensland, Brisbane,, Australia, 3Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology...
  • 26 May 2021
Read More
P MEHTA 1,  T SLATTER 1,  R WALKER 1 1University of Otago, Dunedin, New Zealand Aim: To explore pathways through which amiloride reduces lithium-induced interstitial fibrosis. Background: Lithium therapy is associated with the development of nephrogenic diabetes insipidus (NDI), interstitial fibrosis and...
  • 25 May 2021
Read More
Categories